Prev MonthPrev Month Next MonthNext Month
Metro Detroit Webinar
Thursday, July 09, 2020, 7:30 PM EDT
Category: Events

On behalf of Teva Pharmaceuticals, we are looking forward to your participation in the upcoming program about AJOVY® (fremanezumab-vfrm) injection to be held on Thursday, July 9, 2020.

During this program, we will discuss the role of calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine, with a focus on AJOVY® (fremanezumab-vfrm) injection, an anti-CGRP treatment for the preventive treatment of migraine in adults.

Please see below for the information to access the program:

Date: Thursday, July 9, 2020

Time: 7:30 PM Eastern

Topic:  AJOVY® (fremanezumab-vfrm) Injection: Patient Case Studies for Understanding Migraine

Speaker: Sarah Bruney, MS, ACNP-BC

Michigan State University – Department of Neurology & Ophthalmology

Web Meeting Info:  https://ahmdirect.adobeconnect.com/t91508106/

Phone: 1-888-771-8386 

Passcode:  6565817371


AJOVY is indicated for the preventive treatment of migraine in adults.


Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

Adverse Reactions: The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.

Please see the full Prescribing Information for AJOVY. [https://www.ajovyhcp.com/globalassets/ajovy/ajovy-pi.pdf]

 CO Price Law Disclosure (HB 19-1131)

Contact: [email protected]